HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.
about
The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
P2860
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
HDAC inhibitors enhance nerati ...... nomodulatory antibody in vivo.
@en
HDAC inhibitors enhance nerati ...... nomodulatory antibody in vivo.
@nl
type
label
HDAC inhibitors enhance nerati ...... nomodulatory antibody in vivo.
@en
HDAC inhibitors enhance nerati ...... nomodulatory antibody in vivo.
@nl
prefLabel
HDAC inhibitors enhance nerati ...... nomodulatory antibody in vivo.
@en
HDAC inhibitors enhance nerati ...... nomodulatory antibody in vivo.
@nl
P2093
P2860
P356
P1433
P1476
HDAC inhibitors enhance nerati ...... nomodulatory antibody in vivo.
@en
P2093
Alshad S Lalani
Andrew Poklepovic
Francesca Avogadri-Connors
Jane L Roberts
Laurence Booth
Richard E Cutler
P2860
P304
90262-90277
P356
10.18632/ONCOTARGET.21660
P407
P50
P577
2017-10-09T00:00:00Z